UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
Psomagen seeks KOSDAQ listing using technology exception policy
by Jeong Sae-im
2019-07-10 15:20
Kolon files administrative suit against Invossa license revocation
by Jeong Sae-im
2019-07-09 11:47
SillaJen shareholders panic over exec’s selling of 160,000 stocks
by Jeong Sae-im
2019-07-09 11:45
Kolon TissueGene’s ₩490 billion shares on verge of becoming worthless
by Jeong Sae-im
2019-07-08 12:06
Victims question Kolon CEO’s sincerity in apology
by Jeong Sae-im
2019-07-05 15:14
라인
Samsung, Genentech settle patent dispute on Herceptin biosimilar
by Lee Han-soo
2019-07-05 11:47
Kolon confident to resume US trial on Invossa
by Lee Hye-seon
2019-07-04 14:05
China OKs Alteogen’s Herceptin biosimilar for clinical trials
by Lee Han-soo
2019-07-04 14:04
Regulator revokes Invossa license; Kolon CEO ‘to fight in court’
by Lee Hye-seon
2019-07-03 11:52
BNO BIO to invest $1 million in Israeli biotech venture
by Jeong Sae-im
2019-06-28 16:10
라인
Shareholders in shock over HLB’s phase-3 trial setback
by Jeong Sae-im
2019-06-28 10:47
‘Food and drug ministry alone can’t handle Invossa debacle’
by Jeong Sae-im
2019-06-27 12:45
Oscotech wins exception policy for continued R&D for new drugs
by Jeong Sae-im
2019-06-25 14:11
Despite regulator’s ruling delay, Kolon TissueGene likely to be reviewed for delisting
by Jeong Sae-im
2019-06-20 14:20
294 shareholders file suit against Kolon TissueGene for damage compensation
by Jeong Sae-im
2019-06-14 10:51
라인
Celltrion unveils P3 trial results for rheumatoid biosimilar in Europe
by Lee Han-soo
2019-06-13 16:10
Kolon TissueGene CEO resigns
by Jeong Sae-im
2019-06-07 15:35
[ASCO 2019] ‘Ontruzant demonstrates equal quality to original drug’
by Lee Han-soo, KBR correspondent
2019-06-04 14:17
Kolon’s minority shareholders demand over ₩25 billion in damage
by Jeong Sae-im
2019-06-03 14:53
Invossa inventor sold Kolon shares at highest value
by Jeong Sae-im
2019-06-03 14:52
-
1
2
3
4
5
6
7
8
9
10
다음
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top